Although shock in sepsis is usually managed successfully by conventional medical treatment, a subset of cases do not respond and may require salvage therapies such as veno-arterial extracorporeal membrane oxygenation (VA ECMO) support as well as an attempt to remove endotoxins. However, there are limited reports of attempts to remove endotoxins in patients with septic shock on VA ECMO support. We recently experienced a case of septic shock with severe myocardial injury whose hemodynamic improvement was unsatisfactory despite extracorporeal membrane oxygenation (ECMO) support. Since the cause of sepsis was acute pyelonephritis and blood cultures grew gram-negative bacilli, we additionally applied polymyxin B direct hemoperfusion (PMX-DHP) to the ECMO circuit and were able to successfully taper off vasopressors and wean off ECMO support. To the best of our knowledge, this is the first adult case in which PMX-DHP in addition to ECMO support was successfully utilized in a patient with septic shock. This case indicates that additional PMX-DHP therapy may be beneficial and technically feasible in patients with septic shock with severe myocardial injury refractory to ECMO support.
Japan). [10] To the best of our knowledge, simultaneous PMX-DHP application in adult patients in septic shock under VA ECMO support has not been previously reported. Therefore, we report our experience of applying PMX-DHP to a patient in septic shock due to pyelonephritis with severe myocardial injury refractory to VA ECMO support.
Case Report
A 69-year-old female presented to the emergency department with fever, altered mental status, and right flank pain. CRRT device and to the VA ECMO circuit (Fig. 2 ) in hopes of removing any circulating endotoxin. The access lines of hemoperfusion and CRRT were connected to the arterial line of ECMO (Fig. 3A) ; the return lines of PMX-DHP and CRRT were connected to the venous line of ECMO (Fig.   3B) . We set the ECMO flow to 4-5 L/min while PMX-DHP was applied. The flow of CRRT and hemofiltration ranged between 100 ml/min and 150 mL/min with no significant adverse events or alarm signs indicating false connection between these devices. Neither membrane nor circuit clotting were observed, although anticoagulation was not performed because of progressive thrombocytopenia.
After 3 hours of the PMX-DHP session, we were able to reduce the norepinephrine dose down to half the initial dose and discontinue the vasopressin infusion. The MAP was 86 mmHg and a pulse pressure developed (95/78 mmHg). Laboratory findings at 24 hours after PMX-DHP revealed significantly decreased lactate level to 9.1 mmol/L and troponin I level to 23.6 ng/mL (Fig. 4) .On the fourth hospital day, improved left ventricular systolic function was documented on follow-up echocardiography and then VA-ECMO was disconnected successfully, only after 2 days and 15 hours of maintenance. Although she recovered from refractory septic shock, she suffered from vasopressor induced necrosis of the right hand, ECMO cannulation site dehiscence, and recurrent hematochezia due to ischemic and pseudomembraneous colitis. Unfortunately, she additionally experienced a non-ST segment elevated myocardial infarction on the twentieth hospital day and underwent coronary bypass graft surgery. Eventually, she was discharged to a local hospital for rehabilitation after a three month hospitalization (Fig. 5) . 
Discussion
There are two major hemodynamic disturbances associated with early death in septic shock. [11] One of them is distributive shock, which is characterized by low systemic vascular resistance with preserved cardiac index and the other is cardiogenic shock, which is characterized by decreased cardiac index.
The role of ECMO in adults with septic shock is still controversial. [2] [3] [4] It is well known that ECMO does not filter circulating inflammatory cytokines that can worsen septic shock, [12] and thus, ECMO appears to have little effect in patients with predominantly distributive shock, where heart function is preserved but the increased oxygen demand itself cannot be overcome by ECMO support. [3] Recent studies suggest that ECMO may be beneficial in patients with severe myocardial injury, as it may provide extra time to overcome the hemodynamic instability caused by myocardial dysfunction. [2, 3] In the present case, the patient had severe myocardial injury with global hypokinesia and high troponin I levels, indicating that she may be a suitable candidate for ECMO support. Unfortunately, the hemodynamic support by ECMO was not enough to decrease the lactate level and vasopressor requirement. This may be due to inflammatory mediators causing ongoing distributive shock and septic cardiomyopathy. Recently, an animal study showed that the combined use of ECMO and a blood purification device was helpful in the treatment of endotoxemia. [8] In humans, a case of a septic neonate under VA ECMO support treated by PMX-DHP was reported. [10] In our case, septic shock was accompanied by cardiac dysfunction severe enough to require mechanical support by VA ECMO. Endotoxin removal may have played a role in resolving the cardiogenic shock caused by septic cardiomyopathy, since the elevated troponin I level, a biomarker of myocardial damage, was also reduced after hemofiltration. [16] There are two case reports from Japan that suggest PMX-DHP may be beneficial in septic cardiomyopathy by absorbing inflammatory mediators. [17, 18] There were no adverse events during the concurrent use of ECMO, CRRT, and hemofiltration in our case. We connected the hemofiltration device parallel to the CRRT device, which were then to the VA-ECMO circuit via three-wayconnectors. Connecting such devices was technically feasible, simple, and safe. This came at no surprise, considering that the arterial flow of ECMO (ranged between 3 L and 4 L) was enough to maintain the slow flow (ranged between 100 mL and 150 mL) required to operate the other devices.
In conclusion, we report the first adult case of the use of PMX-DHP in a patient with septic shock and severe myocardial injury who showed minimal hemodynamic response to VA ECMO support. The positive outcome of using PMX-DHP in this patient may be explained by improvement of distributive and cardiogenic shock secondary to the removal of endotoxin. We suggest that PMX-DHP may rescue the refractory septic shock patient with septic cardiomyopathy.
